Related Experiment Video

Updated: Jun 3, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

New phosphatidylinositol 3-kinase inhibitors for cancer

Daniel W Bowles1, Antonio Jimeno

  • 1University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA.

Expert Opinion on Investigational Drugs
|March 15, 2011
PubMed
Abstract

Insights

Targeting the PI3K signaling pathway with novel inhibitors shows promise for cancer treatment. However, identifying predictive biomarkers is crucial for patient selection and therapeutic success.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer therapy is shifting towards targeted agents, moving beyond traditional cytotoxic drugs.
  • The Phosphoinositide 3-kinase (PI3K) signaling pathway is a critical target in numerous human cancers.
  • Inhibiting the PI3K axis presents a promising strategy for various cancer treatments.

Purpose of the Study:

  • To review the rationale for targeting PI3K and its downstream effectors in cancer treatment.
  • To analyze preclinical and clinical data of PI3K and PI3K-mTOR inhibitors.
  • To discuss the current status of these agents in early clinical trials.

Main Methods:

  • Comprehensive literature review of PI3K and PI3K-mTOR inhibitors.
  • Analysis of preclinical studies and early-phase clinical trial data.
  • Examination of single-agent and combination therapy results.

Main Results:

  • Early clinical trials of PI3K and PI3K-mTOR inhibitors have yielded mixed results.
  • Both single-agent and combination therapies are under investigation.
  • The efficacy of these inhibitors appears to be influenced by patient selection.

Conclusions:

  • The clinical success of PI3K and PI3K-mTOR inhibitors hinges on precise patient selection.
  • While PI3K pathway mutations may indicate sensitivity, they are not yet reliable predictive biomarkers.
  • Developing robust predictive biomarkers is essential for realizing the therapeutic potential of these novel anticancer agents.

More Related Videos

Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation10:52

Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation

Published on: January 6, 2016

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...